ALK and non-small cell lung carcinoma: Currently, the first generation ALK TKI (crizotinib) and the second-generation ALK TKIs (alectinib, brigatinib, ceritinib) are both recommended after updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs and Biologics Compendium (NCCN Compendium®) for Non-Small Cell Lung Cancer for the treatment of ALK + NSCLC patients (Pinto et al., 2020; National Comprehensive Cacncer Network and NCCN eBulletin Newsletter).